# Neo Comprehensive

Source: https://onco.cc/drugs/neo-comprehensive/  
OnCo record `neo-comprehensive` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NeoGenomics' gene panels for leukaemia, lymphoma and related blood cancers, reading DNA and RNA in one test.

## Summary

Neo Comprehensive is NeoGenomics' pair of genomic profiling tests for blood cancers. Neo Comprehensive - Heme Cancers analyses genes associated with most haematological cancers of myeloid and lymphoid lineage, and Neo Comprehensive - Myeloid Disorders those of myeloid lineage, each detecting DNA and RNA alterations in one assay. NeoGenomics' latest version adds UBA1 for complex myelodysplastic syndrome cases, reports hotspot mutations and 51 genes associated with clonal haematopoiesis down to 3% variant allele frequency, and gives results in as few as 8 days. The tests sit beside NeoGenomics' cytogenetics, flow cytometry and FISH services.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Also known as: NeoGenomics Neo Comprehensive; Neo Comprehensive - Heme Cancers; Neo Comprehensive - Myeloid Disorders
- Tags: test
- Brand: Neo Comprehensive
- Modality: Genomic profiling tests for blood cancers (DNA and RNA sequencing)
- Mechanism: Next-generation sequencing that detects DNA and RNA alterations in one assay, in genes associated with most blood cancers of myeloid and lymphoid lineage (Heme Cancers) or myeloid lineage only (Myeloid Disorders).

## Notes

- What a result means: findings help classify the blood cancer and estimate risk, and some point to targeted drugs such as FLT3 or IDH inhibitors.
- Not confirmed: the gene counts and regulatory status, which the page does not state, and whether Neo Comprehensive replaced the NeoTYPE profiles this site listed before; NeoGenomics' provider pages in November 2026 no longer name NeoTYPE.

## Sources

- NeoGenomics: haematological cancer testing: https://www.neogenomics.com/providers/oncology-solutions/hematological-cancer

## Connected records

- biomarkers: [FLT3-ITD (internal tandem duplication)](https://onco.cc/biomarkers/flt3-itd/), [FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)](https://onco.cc/biomarkers/flt3-tkd/), [IDH1 R132 mutation](https://onco.cc/biomarkers/idh1-r132/), [IDH2 mutation (R140 and R172)](https://onco.cc/biomarkers/idh2-mutation/), [KIT D816V](https://onco.cc/biomarkers/kit-d816v/), [NPM1 mutation](https://onco.cc/biomarkers/npm1-mutation/), [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Reference laboratories and companion-diagnostic testing](https://onco.cc/technologies/reference-laboratories/)
- companies: [NeoGenomics](https://onco.cc/companies/neogenomics/)
- pathways: [Clonal haematopoiesis (CHIP)](https://onco.cc/pathways/clonal-haematopoiesis/)
- terms: [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)

---
JSON: https://onco.cc/api/v1/entities/neo-comprehensive.json